Greenwich LifeSciences, Inc. (GLSI) insider trading.
In Q3 2026, insiders at Greenwich LifeSciences, Inc. reported 5 non-derivative transactions on 3 Forms 3, 4 and 5: 5 open-market purchases worth $97K and 0 sales.
- Transactions
- 5
- Purchases (P)
- 5
- Sales (S)
- 0
- Net shares, P minus S
- 7,300
- Insiders
- 1
- Last filed
- 2026-07-30
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Patel Snehal | Director, Officer, TenPercentOwner · CEO and CFO | 5 | 5 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-29 | Patel Snehal | P (A) | 700 | $13.1 | 5,611,402 | Form 4 |
| 2026-07-28 | Patel Snehal | P (A) | 1,500 | $13.59 | 5,610,702 | Form 4 |
| 2026-07-27 | Patel Snehal | P (A) | 1,500 | $13.62 | 5,609,202 | Form 4 |
| 2026-07-24 | Patel Snehal | P (A) | 1,100 | $12.88 | 5,607,702 | Form 4 |
| 2026-07-23 | Patel Snehal | P (A) | 2,500 | $13.14 | 5,606,602 | Form 4 |
Transaction codes in this quarter
Get GLSI insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1799788&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · GLSI company page · Greenwich LifeSciences, Inc. on SEC.gov
Questions
Are insiders buying or selling Greenwich LifeSciences, Inc. (GLSI)?
In Q3 2026, insiders at Greenwich LifeSciences, Inc. reported 5 non-derivative transactions on 3 Forms 3, 4 and 5: 5 open-market purchases worth $97K and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Greenwich LifeSciences, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/glsi.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.